Gain Therapeutics, Inc.
GT-02287
Parkinson's disease
Countdown
86days
Catalyst readout · ~ Sep 30, 2026 estimated
What's at stake
A key catalyst for GT-02287 (Parkinson's disease) is expected ~ Sep 30, 2026.
Primary source
· SEC 8-K
verified 12h ago
“The initiation of the Phase 2 study of GT-02287 is anticipated to occur during the third quarter of 2026.”